CJ-1295 DAC
CJC-1295 with Drug Affinity Complex, Modified GRF(1-29) DAC
Overview
CJC-1295 DAC is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH) modified with a drug affinity complex to increase its half-life significantly. It is used in research to study prolonged stimulation of growth hormone secretion.
Research Summary
CJC-1295 DAC represents a specialized development in the study of GHRH mimetics. Unlike standard GRF(1-29), which has a short duration of action, the addition of the DAC allows the peptide to bind covalently to albumin in the bloodstream, effectively extending its half-life from minutes to days. Extensive research has focused on its capacity to sustain elevated pulses of endogenous Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) levels. Clinical data from early trials suggested that a single dose could elevate serum GH and IGF-1 levels for over a week, making it a subject of great interest for therapeutic applications related to GH deficiency and sarcopenia. Research also evaluates its long-term effects on metabolic health and recovery.
Mechanism of Action
CJC-1295 DAC works as a potent GHRH receptor agonist. It binds to the GHRH receptors on the pituitary gland, stimulating the pulsatile release of Growth Hormone. Its unique design involves a maleimidopropionic acid derivative attached to the peptide, which allows it to link to circulating albumin.
By tethering to albumin, the peptide is protected from rapid enzymatic degradation and renal clearance. This continuous delivery mechanism ensures a prolonged, stable physiological effect on the somatotropic axis, differentiating it from the acute, transient stimulation provided by non-conjugated GHRH analogs.
Common Discussion Topics
This compound is for research use only and is not intended for human consumption or clinical use.
Discussion
Commenting as guest — your email won't be shown publicly.
No comments yet. Be the first to start the discussion!
Stay Updated
Get the latest peptide research insights delivered to your inbox.